DOTMP Kit Formulations for Radioisotope Radiolytic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radionuclide complex formulations face challenges in achieving high radiochemical purity (RCP) and maintaining it until injection, due to radiolytic degradation and pH control issues, which affect biodistribution and therapeutic effectiveness.
Innovation Solution
A pharmaceutically-acceptable kit formulation with a two-part buffering system, comprising lyophilized DOTMP, Carbonate, and NaOH or KOH, along with an optional Calcium solution and Phosphate buffer, is used to prepare a Radioisotope-DOTMP chelate, ensuring precise pH control during complex formation and minimizing radiolytic degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a radioisotope is combined with DOTMP to form a radiopharmaceutical, then the therapeutic effectiveness for bone tumors is improved, but radiolytic degradation occurs reducing radiochemical purity over time
Solution Approach 1:
The patent performs pH adjustment and buffering before the radioisotope is introduced to the kit. The lyophilized DOTMP is pre-mixed with buffering agents (sodium carbonate, sodium phosphate) and lyophilized, so that when the radioisotope solution is added, the pH is already optimized for stable complex formation, minimizing radiolytic degradation during the radiopharmaceutical preparation and storage.
Solution Approach 2:
The patent controls the pH parameter within a specific range (7.0-8.5) by using a buffer system comprising sodium carbonate and sodium phosphate. This pH control prevents radiolytic degradation of the radioisotope-DOTMP complex, maintaining high radiochemical purity while ensuring therapeutic effectiveness.
2Ease of manufacture
If the pH is not precisely controlled during complex formation, then the preparation process is simpler, but radiochemical purity and biodistribution are compromised
Solution Approach 1:
The kit is designed as a self-buffering system where the lyophilized DOTMP is pre-mixed with sodium carbonate and sodium phosphate buffering agents. When the radioisotope solution is added, the buffer system automatically maintains the pH within the optimal range (7.0-8.5), eliminating the need for external pH adjustment and simplifying the preparation process while ensuring manufacturing precision.
Solution Approach 2:
The patent creates a composite lyophilized mixture of DOTMP with buffering agents (sodium carbonate and sodium phosphate). This composite material provides both the chelating function and the pH-buffering function in a single component, simplifying the overall preparation process while maintaining precise pH control for optimal radiochemical purity.
3Reliability
If excess chelant is used to ensure complete complex formation, then complex formation is improved, but calcium binding occurs causing harmful cardiac effects
Solution Approach 1:
The patent optimizes the molar ratio of DOTMP to radioisotope within a specific range (1:1 to 3:1) rather than using large excesses of chelant. The buffered pH environment (7.0-8.5) ensures complete complex formation within this optimized ratio, preventing excess free chelant from binding calcium and causing cardiac toxicity, while still achieving complete complex formation for therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit achieves a high RCP of at least 97% and maintains stability, facilitating consistent and reproducible preparation of a therapeutically effective bone-seeking drug with optimal biodistribution, reducing undesirable side effects from soft tissue uptake.
Implementation Method 1
a two part buffering system, namely, Carbonate followed by Phosphate
Implementation Method 2
chelates of Sm-153 and Lu-177 with DOTMP
Data Source
Figure 1
Figure 2
AI summary
This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression.